Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Assets (2016 - 2025)

Historic Assets for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to $45.7 million.

  • Immucell's Assets rose 288.25% to $45.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $45.7 million, marking a year-over-year increase of 288.25%. This contributed to the annual value of $45.1 million for FY2024, which is 295.01% up from last year.
  • Immucell's Assets amounted to $45.7 million in Q3 2025, which was up 288.25% from $46.7 million recorded in Q2 2025.
  • Immucell's Assets' 5-year high stood at $46.7 million during Q2 2025, with a 5-year trough of $39.6 million in Q1 2021.
  • Over the past 5 years, Immucell's median Assets value was $44.5 million (recorded in 2021), while the average stood at $44.4 million.
  • As far as peak fluctuations go, Immucell's Assets surged by 1786.41% in 2022, and later crashed by 765.81% in 2023.
  • Over the past 5 years, Immucell's Assets (Quarter) stood at $44.5 million in 2021, then rose by 0.89% to $44.9 million in 2022, then fell by 2.35% to $43.8 million in 2023, then increased by 2.95% to $45.1 million in 2024, then rose by 1.4% to $45.7 million in 2025.
  • Its Assets stands at $45.7 million for Q3 2025, versus $46.7 million for Q2 2025 and $45.6 million for Q1 2025.